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Abstract
Aim: Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is an important negative regulator of T-cell
responses. CTLA-4 polymorphisms have been confirmed to be associated with several autoimmune diseases
such as systemic lupus erythematosus (SLE). We analyzed the role of CTLA-4 polymorphism at positions 1661
and 1722 in Iranian patients suffering from SLE.
Methods: One hundred and eighty SLE patients and 304 ethnically and age-matched healthy controls were stud-
ied. Polymerase chain reaction restriction fragments length polymorphism (PCR-RFLP) was used to analyze the
genotype and allele frequencies of these polymorphisms.
Results: There was no significant association between the studied genotypic and allelic frequencies between SLE
patients and the controls. Although the TC genotype in 1722TC polymorphism was more common among the
control group, the correlation was not statistically significant.
Conclusion: Our results suggest that the 1661AG and 1722TC polymorphisms in the promoter region of the
CTLA-4 gene does not play any role in genetic susceptibility to SLE. However, further studies on larger sample
sizes are needed to approve our results.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex
inflammatory disease characterized by autoantibody
production.1 The disease is more common in women
but found in different racial and ethnic groups. It is
more frequently reported in individuals in the second,
third or fourth decades of life.2 SLE afflicts more than 1
million individuals in the US and 3.2–14.1 cases per
100 000 in women of European descent.3,4 The disease
is reported in 40 per 100 000 of the Iranian popula-
tion.5 The etiology of the disease is unknown but is
thought to be caused by both genetic and environmental
factors.6 The expression of Cytotoxic T lymphocyte-asso-
ciated antigen-4 (CTLA-4) is increased in patients with
active SLE.7 CTLA-4 is an important negative regulator of
T-cell responses, and its dysregulation has the potential
to affect the pathogenesis of SLE by altered activation of
T-cells to self-antigens.1 Inappropriate T-cell-dependent
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expansion of autoreactive B cells is considered to play a
role in the production of pathogenic autoantibodies8 in
multiple organs, including kidneys, heart, lung, joints
and immune system.9 The CTLA-4 gene is located within
the risk region on chromosome 2q33 and several poly-
morphisms have been reported in this gene,10 CTLA-4
polymorphisms have been confirmed to be associated
with several autoimmune diseases, such as Graves’ dis-
ease, type I diabetes, celiac disease, autoimmune thyroid
disease, rheumatoid arthritis and multiple sclerosis and
SLE.11 Two of these polymorphisms are located within
the promoter region: A/G transition at position
166112–14 and T/C transition at position 1722.13,15
Using a case-control study design, we have determined
the role of CTLA-4 gene polymorphisms in the promoter
regions in SLE pathogenesis.
MATERIALS AND METHODS
Patients
One hundred and eighty SLE patients (15 males and
165 females) with a mean age of 10.45  32.99 years
(range 13–70 years) were enrolled in the study. Three
hundred and four ethnically and age-matched healthy
controls (23 males and 281 women) with no history of
any autoimmune diseases were also recruited from the
Azar Fifth Teaching Hospital affiliated to Gorgan Uni-
versity of Medical Sciences, Gorgan, Iran. All the SLE
patients fulfilled the American College of Rheumatol-
ogy 1997 revised criteria for SLE.16 The study was
approved by the local ethics committee and a written
informed consent was obtained from each patient.
DNA extraction and genotyping
The DNA from the patients and controls were extracted
from their peripheral blood with a DNA extraction kit
(Roche Applied Science, Penzberg, Germany) according
to the standard protocol from the manufacturer.
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) was used to analyze the
polymorphisms at positions 1661 and 1722.
Promoter-region polymorphisms were genotyped as
follows using a single primer set: forward 5′-CTAAGAG
CATCCGCTGCACCT-3′ and reverse 5′-TTGGTGTGATG
CACAGAAGCCTTT-3′. Amplification was carried out
after initial denaturation at 94°C (5 min), followed by
30 cycles at 94°C (15 s), 58°C (30 s), 72°C (45 s),
and a final extension at 72°C (7 min). The PCR prod-
ucts were digested using restriction enzyme MseI or
BbvI (New England BioLabs, Hitchin, UK) at 37°C for
4 h and then were analyzed on 2% agarose gel using
ethidium bromide staining. The amplified DNA for
1722TC was 486 bp fragment (T allele) or two
fragments of 270 and 216 bp (C allele). The 1661AG
polymorphism was determined by detecting a 486 bp
fragment (G allele) or two fragments of 347 and
139 bp (A allele).
Statistical analysis
The frequency of alleles and genotypes were assessed
using direct counting. Chi-square and Fisher’s exact test
were used to compare the distributions and association
of alleles and genotypes in the patients and the controls.
P-values < 0.05 were considered statistically significant.
The strength of the association between different groups
and alleles or genotypes of polymorphism was estimated
using odds ratios (OR) and 95% confidence intervals
(CI). Statistical analysis was conducted with STATA (v8)
software (StataCorp., College Station, TX, USA).
Linkage disequilibrium and haplotype
analysis
Estimated haplotype frequencies and testing for linkage
disequilibrium between pairs of polymorphisms in the
cases and controls were calculated using the EHPLUS
program,17 which provides log likelihood, chi-square
and the number of degrees of freedom. To test for heter-
ogeneity in haplotype frequencies between the cases
and controls, the likelihood ratio test was used.
RESULTS
Blood samples from 180 SLE patients and 304 controls
were successfully genotyped for the 1661AG and
1722TC in the promoter regions of the CTLA-4 gene.
Genotype and allele frequencies of the 1661AG and
1722TC polymorphisms are shown in Tables 1 and 2,
respectively. There was no statistically significant differ-
ence in the genotype and allele frequencies at the
1661 and 1722 sites between SLE patients and
healthy controls. There was no significant linkage dis-
equilibrium (LD) between the markers both in cases
and controls (P > 0.05) in our population. The esti-
mated haplotype frequencies in cases and controls are
given in Table 3. No significant differences for esti-
mated haplotype frequencies were found between cases
and controls.
DISCUSSION
Although the definite etiopathogenesis of SLE remains
unclear, evidence indicates that CTLA-4 polymorphisms
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play an important role in susceptibility to SLE. Some
studies have reported a significant correlation between
CTLA-4 polymorphisms and SLE.12,13,15,18,19 On the
other hand, several studies have failed to show any
association between SLE and CTLA-4 polymor-
phisms.14,20–23 In this study no association was
observed between CTLA-4 polymorphisms and SLE in
the Iranian population. The results demonstrated no
difference between the genotype and allele frequencies
for the 1661 site between patients and controls. In
line with our results, studies conducted in China,19
Korea,13 Japan,14 Malaysia21 and the US20 did not find
a positive correlation between the polymorphism and
SLE. Our results and that of previous studies indicate
that ethnicity and geography do not affect the 1661AG
polymorphism as different populations showed similar
results on the test. Other polymorphisms such 1722TC
were also not associated with SLE. This is compatible
with the results of other reports.14,20–22
Our study showed a insignificantly higher frequency
for the TC genotype among the controls. Khalaf et al.
reported a strong association between 1722TC poly-
morphism and SLE.12 An-ping et al. also studied the
1722TC polymorphism and showed significantly higher
presence of TC genotype in SLE patients.19 On the con-
trary, corroborating with our results, Hudson et al.
reported that the TC genotype was more frequently
reported among the healthy controls, adding that the
correlation was statistically significant.13
The LD analysis performed on 1661AG and
1722TC polymorphisms revealed no differences
between the cases and controls in our study. In associa-
tion with 1722TC polymorphism, our results indicate
that our population might be different from other Asian
people such as the Chinese and the Koreans, as the
results were inconsistent across different ethnic popula-
tions.12,13,18,19 While several studies have reported
Table 1 Genotypic distribution and allelic frequencies of 1661 AG CTLA-4 polymorphisms in Iranian SLE patients and healthy
controls




P-value OR (95% CI)
Genotype
AA 66 (36.7) 112 (36.8) 0.49 0.97 (0.66–1.43)
AG 59 (32.8) 103 (33.9) 0.42 0.94 (0.63–1.39)
GG 55 (30.6) 89 (29.3) 0.49 1.02 (0.68–1.53)
Allele
A 190 (52.8) 327 (53.8) 0.32 0.89 (0.59–1.32)
G 170 (47.2) 281 (46.2) 0.5 0.98 (0.67–1.44)
Table 2 Genotypic distribution and allelic frequencies of 1722 TC CTLA-4 polymorphisms in Iranian SLE patients and healthy
controls




P-value OR (95% CI)
Genotype
TT 160 (88.9) 270 (88.8) 0.55 1 (0.56–1.81)
TC 13 (7.2) 21 (6.9) 0.46 0.9 (0.45–1.83)
CC 7 (3.9) 13 (4.3) 0.51 0.9 (0.35–2.31)
Allele
T 333 (92.5) 561 (92.3) 0.59 1.01 (0.39–2.62)
C 27 (7.5) 47 (7.7) 0.52 0.96 (0.53–1.76)
Table 3 Estimated haplotype frequencies of CTLA polymor-
phisms in patients and controls
Allele at locus 1 Allele at locus 2 Haplotype frequency
Cases Control
1 1 0.485022 0.499411
1 2 0.040401 0.038418
2 1 0.444356 0.426576
2 2 0.030220 0.035595
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1661AG and 1722TC polymorphisms to be more
common in SLE patients, this is the first study to show
the association among Iranians. Hence, further studies
on larger sample sizes are needed to approve our
results.
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